Nivolumab (BMS-936558) 是一种程序性死亡受体-1 (PD-1) 阻断人 IgG4 抗体,用于 晚期(转移性)非小细胞肺癌。 Cas No.946414-94-4SDF 别名纳武单抗; BMS-936558; ONO-4538; MDX-1106 化学名N/A Canonical SMILES[Nivolumab] 分子式N/A分子量143599.09 ...
BMS-936558-01 Nivolumab 注射液的适应症是非小细胞肺癌 此药物由Bristol-Myers Squibb Company/ Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company/ 百时美施贵宝(中国)投资有限公司生产并提出实验申请,[实验的目的] 在经组织学证实的IV 期NSCLC 受试者中比较nivolumab +伊匹木单抗联合化疗对比化疗的疗效...
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): a double-blinded, randomized, phase III trial. J Clin Oncol. 2017;35(suppl 4S):abstract 2....
Nivolumab(BMS-936558; ONO-4538; MDX- Nivolumab 是一种PD-1抗体类抑制剂,用于晚期(转移性)非小细胞肺癌的研究。 MCE 的所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务 生产商:MedChemExpress(MCE) 分子量:143599.09 体外:Nivolumab 与表达 PD-1 的 CHO 细胞结合, EC50 为 1.66 nm, 但不与亲...
Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014, 124, 291-291.Lesokhin AM, Ansell SM, Armand P et al. (2014) Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with ...
Nivolumab (anti-PD-1; BMS- 936558, ONO-4538) in combination with platinum- based doublet chemotherapy in advanced non-small cell lung cancer [Abstract 8113]. Journal of Clinical Oncology (Meeting Abstracts), 32(suppl 5s).Antonia S J, Brahmer JR, Gettinger SN, et al. Nivolumab (anti- ...
Nivolumab (Anti-PD-1; BMS- 936558, ONO- 4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy. Radiation Oncol. 2014; 90:S32.Rizvi NA,Antonia SJ,Shepherd FA,et al.Nivolumab ( Anti-PD-1;BMS-...
Amin A Ernstoff M S Infante J R et al. A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC) J Clin Oncol 2013. 31 (suppl):abstr TPS4593...
A phase III, ran- domized, double-blind study of nivolumab (anti-PD-1; BMS- 936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). J Clin Oncol 2013;31(15 Supp):TPS9106....
Nivolumab (Anti-PD-1; BMS- 936558, ONO- 4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy. Radiation Oncol. 2014; 90:S32.Rizvi NA, Antonia SJ, Shepherd FA, et al. Nivolumab (anti-PD-1; ...